Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 13, 2023
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2022
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsKatharina Kusejko, Nadine Tschumi, Sandra E Chaudron, et al.
Cancers|December 30, 2025
Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort CollaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2025
Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohortWin Min Han, Lene Ryom, Caroline A Sabin, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 13, 2023
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2022
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsKatharina Kusejko, Nadine Tschumi, Sandra E Chaudron, et al.
Cancers|December 30, 2025
Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort CollaborationAlisa Timiryasova, Lauren Greenberg, Pere Domingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2025
Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohortWin Min Han, Lene Ryom, Caroline A Sabin, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Pageof 11